![]() ![]() Additional risks and factors are identified under “Risk Factors” in QuidelOrtho’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on February 23, 2023, and subsequent reports filed with the Commission. The following factors, among others, could cause actual results to differ from those set forth or implied in the forward-looking statements: the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the business combination the ability to retain key employees and other economic, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of today and are subject to significant risks and uncertainties. These statements in this press release may be identified by words such as “may,” “will,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue” or similar words, expressions or the negative of such terms or other comparable terminology. These statements include any statements contained herein that are not strictly historical, including, but not limited to, QuidelOrtho's preliminary revenue results for the quarter ended April 2, 2023, commercial, integration and other strategic goals, future financial and operating results, and future plans, objectives, strategies, expectations and intentions. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. As we look ahead, our supply chain is improving, we are focused on our key growth drivers and we are confident in our ability to deliver sustainable high-single-digit growth over the coming years.” “Our team delivered solid non-respiratory revenue growth across all major geographic regions, with notable strength in China, demonstrating the power of our newly created scale and breadth of offerings across the diagnostics continuum, as well as the durability of our business model. This strong start to the year was supported by delivering more instruments driving strong results in our Labs business as well as better-than-expected results in the Point of Care business,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho. “After an exceptional fourth quarter of 2022, I am very pleased with our sustained momentum in the first quarter of 2023, which was ahead of expectations. The preliminary revenue results described herein are based on management’s initial analysis for the first quarter ended Apand are subject to adjustments based on the Company’s completion of its quarter-end financial close process. The increase in first quarter revenue results was driven by our Labs business unit, including an approximate $21 million settlement related to one of our collaboration agreements. Non-respiratory product revenue is expected to be in the range of $578 million to $583 million, representing 5% growth on a supplemental combined basis and 7% growth on a constant currency basis at the midpoint. Respiratory product revenue is expected to be in the range of $262 million to $267 million, including COVID-19 product revenue of $212 million to $217 million. The Company expects total revenues in the first quarter of 2023 to be in the range of $840 million to $850 million. SAN DIEGO, CA - QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the first quarter ended April 2, 2023. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |